Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Mark Pegram, Richard Pietras, Chau T. Dang, Rashmi Murthy, Thomas Bachelot, Wolfgang Janni, Priyanka Sharma, Erika Hamilton, Cristina Saura
Summary: Breast cancer with expression of ER and/or PR and overexpression/amplification of HER2 represents a small percentage of all breast cancers in the US. Current treatment for HR+/HER2+ BC includes anti-HER2 monoclonal antibodies plus chemotherapy, but more targeted combinations should be investigated. Dual HR and HER2 pathway targeting is a rational approach to prevent treatment resistance, although limited clinical trial data is available. Attenuating other signaling pathways involved in crosstalk between receptors is also under investigation. Combined receptor blockade targeting HER2 and ER has scientific and clinical rationale for advanced-stage HR+/HER2+ disease.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Oncology
Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Malapelle
Summary: This study discusses the advantages and limitations of different ctDNA testing methods in liquid biopsy and focuses on the abilities of ddPCR and NGS in identifying ESR1 mutations. The importance of meticulous sample handling and timely analysis is emphasized, as well as the detection of sub-clonal ESR1 mutations.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney
Summary: This study investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The combination therapy demonstrated antitumor activity, but had high rates of ILD/pneumonitis and severe transaminase elevations, which does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.
Article
Genetics & Heredity
Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L. Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R. Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A. Rejto, Woong-Yang Park, Zhengyan Kan
Summary: A comprehensive analysis of genomic and transcriptomic changes in tumors from patients receiving CDK4/6 inhibitor therapy plus endocrine therapy revealed novel molecular features associated with resistance and potential targets to overcome it.
Article
Oncology
Alessandra Fabi, Giuseppe Buono, Emilio Bria, Giampaolo Bianchini, Giuseppe Curigliano, Michelino De Laurentiis, Sabino De Placido, Lucia Del Mastro, Valentina Guarneri, Daniele Generali, Lorenzo Livi, Vito Lorusso, Filippo Montemurro, Fabio Puglisi, Paolo Vigneri, Alberto Zambelli, Grazia Arpino
Summary: The treatment strategy for HR+/HER2- metastatic breast cancer is still under debate in clinical practice. In order to address this issue, we conducted a Delphi survey and summarized the consensus among clinicians on key questions regarding cancer treatment. The survey results showed a high level of consensus among the majority of the questions.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K. Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano
Summary: This study evaluated the efficacy and safety of the combination of the anti-PD-1 antibody nivolumab and the CDK4/6 inhibitor abemaciclib in hormone receptor-positive breast cancer. The combination therapy was found to be effective but caused severe and prolonged immune-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Lawrence G. Lum, Zaid Al-Kadhimi, Abhinav Deol, Vidya Kondadasula, Dana Schalk, Elyse Tomashewski, Patricia Steele, Kristie Fields, Melissa Giroux, Qin Liu, Lawrence Flaherty, Michael Simon, Archana Thakur
Summary: The study evaluated the efficacy and immune responses of HER2 BATs in metastatic HER2- breast cancer as immune consolidation after chemotherapy. Results showed that HER2 BATs increased the proportion of patients who were stable at 4 months, improved overall survival, and enhanced antitumor immune responses. Future studies combining HER2 BATs with checkpoint inhibitors or other immunomodulators may further improve clinical outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Aditya Bardia, Ingrid Mayer, Eric Winer, Hannah M. Linden, Cynthia X. Ma, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching-Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris Chan, Komal Jhaveri
Summary: This study evaluated the safety and efficacy of GDC-0810 in patients with ER+ advanced/MBC. The results showed that GDC-0810 was safe and tolerable, and had preliminary anti-tumor activity in these patients.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Jinhao Wang, Yaxin Liu, Yuehua Liang, Yue Zhang, Hang Dong, Tiantian Zheng, Jianjun Yu, Pan Du, Shidong Jia, Bonnie L. L. King, Jing Wang, Xiaoran Liu, Huiping Li
Summary: The determinants of outcome for younger vs. older patients with hormone receptor-positive/HER2-negative metastatic breast cancer were evaluated. The age of patients did not significantly affect the prognosis in this study. These findings support the development of biomarker-driven treatment strategies for these patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Matthew Loft, Sheau Wen Lok, Richard De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton, Michelle Nottage, Vanessa Wong, Louise Nott, Ian M. M. Collins, Javier Torres, Frances Barnett, Janine M. M. Lombard, Peter Gibbs, Lucy Gately
Summary: The study aimed to investigate the efficacy of combining endocrine therapy (ET) with dual anti-HER2 targeted therapy and chemotherapy in HER2 + /HR + breast cancer patients. The results showed that adding ET during first-line chemotherapy in combination with dual anti-HER2 therapy significantly improved 5-year progression-free survival (PFS) and overall survival (OS), with no significant safety concerns.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biology
Viola Cogliati, Serena Capici, Francesca Fulvia Pepe, Pierluigi di Mauro, Francesca Riva, Federica Cicchiello, Claudia Maggioni, Nicoletta Cordani, Maria Grazia Cerrito, Marina Elena Cazzaniga
Summary: CDK4/6 inhibitors in combination with endocrine therapy are the best treatment option for advanced breast cancer. However, the optimal strategy after treatment failure remains unclear. This review analyzes resistance mechanisms and clinical trial results to provide a comprehensive overview.
Article
Medicine, Research & Experimental
Elena Peruzzi, Lorenzo Gerratana, Marcella Montico, Bianca Posocco, Serena Corsetti, Michele Bartoletti, Sara Gagno, Marco Orleni, Elena De Mattia, Massimo Baraldo, Erika Cecchin, Fabio Puglisi, Giuseppe Toffoli, Rossana Roncato
Summary: This study investigates the effect of genetic polymorphisms in ADME genes on the safety profiles of CDKis and identifies several polymorphisms associated with treatment response. These findings are significant for understanding the interindividual variability in CDKis responses.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Erik S. Knudsen, Emily Schultz, Deanna Hamilton, Kris Attwood, Stephen Edge, Tracey O'Connor, Ellis Levine, Agnieszka K. Witkiewicz
Summary: This article reports a real-world experience related to the use of CDK4/6 inhibitors for the treatment of metastatic hormone receptor-positive and HER2-negative breast cancer, focusing on clinical and demographic features associated with progression-free survival.
Article
Oncology
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Summary: This study analyzed clinical practice data of MBC patients in the US using the Flatiron Health Analytic Database and found that first-line treatment with palbociclib plus an aromatase inhibitor significantly improved overall survival and progression-free survival in HR+/HER2- MBC patients.
Article
Oncology
C. Sessa, J. Balmana, S. L. Bober, M. J. Cardoso, N. Colombo, G. Curigliano, S. M. Domchek, D. G. Evans, D. Fischerova, N. Harbeck, C. Kuhl, B. Lemley, E. Levy-Lahad, M. Lambertini, J. A. Ledermann, S. Loibl, K. -A. Phillips, S. Paluch-Shimon
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
Summary: This prospective trial examined the safety of COVID-19 vaccines in patients with thoracic cancer receiving anticancer treatments. The results showed no safety concerns and a low rate of vaccine-related adverse events. The study supports prioritizing vaccination for lung cancer patients undergoing active treatment.
CLINICAL LUNG CANCER
(2023)
Article
Genetics & Heredity
Eva Blondeaux, Matteo Lambertini, Giulia Buzzatti, Carla Bruzzone, Marina Baraga, Roberta Pisani, Lucia Del Mastro, Paolo Pronzato, Liliana Varesco, Luigina Bonelli
Summary: This study evaluated the experience and retention of information in women who underwent nurse-driven genetic counseling for BRCA testing. The majority of women had a positive experience and retained information regarding their personal and familial cancer risk management. However, they showed a poor ability to estimate cancer risk in BRCA mutation carriers and in the general population.
JOURNAL OF GENETIC COUNSELING
(2023)
Article
Obstetrics & Gynecology
C. Massarotti, G. Asinaro, M. G. Schiaffino, C. Ronzini, I. Vacca, M. Lambertini, P. Anserini, L. Del Mastro, A. Cagnacci
Summary: This study aimed to evaluate the efficacy of vaginal oxygen and hyaluronic acid on genito-urinary symptoms of breast cancer survivors. Treatment with vaginal oxygen and hyaluronic acid every 15 days improved genito-urinary symptoms of breast cancer patients. However, additional studies are needed to determine the optimal treatment interval, duration, and long-term benefits.
Article
Oncology
Prudence A. Francis, Gini F. Fleming, Istvan Lang, Eva M. Ciruelos, Herve R. Bonnefoi, Meritxell Bellet, Antonio Bernardo, Miguel A. Climent, Silvana Martino, Begona Bermejo, Harold J. Burstein, Nancy E. Davidson, Charles E. Geyer, Barbara A. Walley, James N. Ingle, Robert E. Coleman, Bettina Muller, Fanny Le Du, Sibylle Loibl, Eric P. Winer, Barbara Ruepp, Sherene Loi, Marco Colleoni, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan
Summary: Clinical trials often have multiple endpoints that mature at different times. Initial reports are based on the primary endpoint and may be published before all planned co-primary or secondary analyses are available. Clinical Trial Updates allow for the dissemination of additional results from studies in which the primary endpoint has already been reported. After a median follow-up of 12 years, the Suppression of Ovarian Function Trial (SOFT) shows that adjuvant endocrine therapy with tamoxifen plus ovarian function suppression (OFS) provides significant improvement in disease-free survival (DFS) and overall survival (OS) for premenopausal women with hormone receptor-positive breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Olivia Pagani, Barbara A. Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry L. Gomez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis
Summary: The combined analysis of SOFT-TEXT compared the outcomes of 4,690 premenopausal women with ER/PgR+ early breast cancer randomly assigned to exemestane + OFS or tamoxifen + OFS. Exemestane + OFS showed significant improvement in DFS and DRFI, but not overall survival, compared to tamoxifen + OFS. This study provides guidance for selecting patients who may benefit from exemestane over tamoxifen in the setting of OFS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.
Article
Oncology
Paola Quarello, Angela Toss, Paola Berchialla, Maurizio Mascarin, Matteo Lambertini, Marta Canesi, Giuseppe Maria Milano, Lorena Incorvaia, Giuseppe Luigi Banna, Fedro Peccatori, Andrea Ferrari
Summary: This study aims to explore the attitude of Italian healthcare professionals towards sexual health communication with AYA patients. The findings reveal that lack of preparation and embarrassment are barriers to communication, and less than 5% of clinicians received specific training on sexual health issues in AYA patients.
Article
Medicine, Research & Experimental
Leisha A. Emens, Sherene Loi
Summary: Immunotherapy, specifically targeting the PD-1/PD-L1 axis, is an effective treatment for cancer that utilizes the immune system's abilities with potential lasting effects. Pembrolizumab, a PD-1 inhibitor, in combination with neoadjuvant chemotherapy followed by adjuvant pembrolizumab, improves survival rates for high-risk early-stage TNBC, regardless of tumor PD-L1 expression. For metastatic TNBC, pembrolizumab combined with chemotherapy is the standard first-line therapy for PD-L1(+) TNBC, leading to improved overall survival.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
(2023)
Review
Genetics & Heredity
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
Summary: Breast cancer is a widely prevalent and deadly malignancy, with brain metastases being a significant contributor to mortality. The formation, progression, and colonization of primary breast tumors and subsequent brain metastases involve diverse molecular pathways, which complicates their clinical management. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. This review aims to highlight the biological mechanisms of breast cancer brain metastases and discuss available and emerging treatment strategies for managing this complex disease.
Review
Oncology
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Giuseppe Curigliano
Summary: HER2-positive metastatic breast cancer is a subtype of breast cancer with aggressive behavior and sensitivity to HER2-targeted agents. Antibody-drug conjugates (ADCs), such as T-DM1 and T-DXd, have shown improved clinical outcomes in this subtype. However, resistance to these ADCs still occurs, highlighting the need for understanding the underlying mechanisms.
Meeting Abstract
Oncology
Dejan Juric, Nicholas Turner, Sherene Loi, Fabrice Andre, Stephen K. Chia, Komal Jhaveri, Patrick Neven, Rebecca Dent, Eva Ciruelos, Mukta Joshi, Estelle Roux, Heather Patino, Murat Akdere, Hope Rugo
Meeting Abstract
Oncology
Roberto A. Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, Sherene Loi, Vincent De Jong, Jodi M. Carter, Torsten Nielson, Samuel Leung, Nazia Riaz, Giuseppe Curigliano, Carmen Criscitiello, Vincent Cockenpot, Matteo Lambertini, Vera Suman, Barbro Linderholm, John W. M. Martens, Carolien H. M. van Deurzen, Mieke Timmermans, Tatsunori Shimoi, Shu Yazaki, Masayuki Yoshida, Sung-Bae Kim, Hee Jin Lee, Maria Vittoria Dieci, Guillaume Bataillon, Anne Salomon, Fabrice Andre, Marleen Kok, Sabine Linn, Matthew P. Goetz, Stefan Michiels
Meeting Abstract
Oncology
Ruth O'Regan, Yi Zhang, Gini F. Fleming, Prudence Francis, Roswitha Kammler, Giuseppe Viale, Istvan Lang, Meritxell Bellet Ezquerra, Herve R. Bonnefoi, Sherene Loi, Marco Colleoni, Catherine A. Schnabel, Kai Treuner, Meredith Regan
Review
Oncology
Eleonora Nicolo, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
Summary: HER2-low expression is an essential biomarker for treatment selection in breast cancer, and recent clinical trials have shown promising results with novel HER2-targeted therapies. It is important to develop more sensitive and reliable methods for HER2 testing and scoring to accurately identify patients who may benefit from these treatments.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)